Authors
Latest:
Clinical Overview: Comparison of Anti-Amyloid Monoclonal Antibodies for Alzheimer DiseaseAducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Latest:
Looking Toward the Future of CDI ManagementClosing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
Latest:
Breaking the Bank: Financial Toxicity in Cancer CareThe increasing economic burden of treatment may impact patient outcomes.
Latest:
GOLD Guidelines Provide Recommendations on Managing COPDPivotal resource helps health care professionals diagnose, manage, and prevent this group of lung diseases.
Latest:
Clinical Overview: Treatment Recommendations for Pneumococcal DiseaseTreatment for community-acquired pneumococcal disease is dependent on patient-specific factors, whereas prevention with vaccinations is dependent on age and comorbidities.
Latest:
Precision Oncology: Expanding Therapeutic Horizons With Trastuzumab DeruxtecanThe tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.
Latest:
Considerations for RSV Prevention in Special Patient PopulationsOlder adults, patients with weakened immune systems, individuals living in long-term facilities, and those with underlying cardiopulmonary disease are at a higher risk of developing severe RSV infection outcomes.
Latest:
Point-of-Care Testing Offers New Opportunities for Pharmacy TechniciansBecoming experts in medical billing for point-of-care testing offers a new avenue for technicians to excel and show their value.
Latest:
Revolutionizing Outpatient Oncology Care: The Seamless Integration of Artificial IntelligenceArtificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.
Latest:
Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple MyelomaIntegration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.
Latest:
Proper Use of Automation in Hazardous Drug Compounding PharmaciesAlthough robotics can be instrumental in assuring sterility and reducing the overall number of potential hazardous drug exposure events, certain tasks require vigilant oversight.
Latest:
Bispecific T-Cell–Engaging Antibodies in B-Cell Lymphoma: Efficacy, Safety, and Practical ConsiderationsThis article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.
Latest:
Specialty Drug Commercialization Process and ConsiderationsAs specialty drugs move through clinical trials and preparations for commercialization begin, significant attention is warranted to this process considering the massive investments that would have been already made in the product up to this point.
Latest:
Use of Lutetium Lu-177 Vipivotide Tetraxetan to Treat Metastatic Castration-Resistant Prostate CancerThe FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.
Latest:
Only a Phone Call Away: The Development of a Transplant Telepharmacy Consult Service For a Large Medical SystemTransplant patients must adhere to lifelong regimens and those caring for them must consider their regimen as the patients intersect with different parts of the health care system.
Latest:
Making “Rheum” for Biosimilars: Overcoming ReluctanceDespite the proven efficacy of biosimilars, both patients and health care providers often have some reluctance when switching from an originator drug to a biosimilar.
Latest:
Can Flexibility Fix Pharmacies? The Case for Contingent WorkersIt’s time for pharmacies to take a page out of the books of hospitals and tech companies by expanding and streamlining their use of contingent labor.
Latest:
Patient Navigation in the Specialty Pharmacy SpaceLack of access to novel therapies, especially within the cancer space, initiated the road to patient navigation.
Latest:
What’s Ahead in the Adalimumab Biosimilar Pipeline in DermatologyFDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.
Latest:
You Previously Qualified for a Small Dispenser DSCSA Exemption. Now What?As welcome as this compliance extension may be for those who qualify, it is critical they understand both their current and future regulatory obligations.
Latest:
Semaglutide Carries Potential Risk of Worsening Diabetic RetinopathyDespite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.
Latest:
Updates in Cancer Prevention and Screening for 2025: A Pharmacist PrimerPharmacists play a vital role in cancer prevention and early detection by educating patients on risk factors, counseling on screening guidelines, and promoting adherence to evidence-based recommendations for common cancers, such as breast, cervical, colorectal, lung, prostate, and skin cancer.
Latest:
Bexagliflozin (Brenzavvy): Advancing Diabetes Management With SGLT-2 InhibitionBeyond its primary role in diabetes treatment, SGLT-2 inhibitors have demonstrated versatility in various health aspects, offering benefits beyond glucose reduction.
Latest:
The Role of Neoadjuvant Immunotherapy Advances in Resectable Stage III MelanomaNADINA trial results support a new standard of care for these patients.
Latest:
Patient-Controlled Analgesia: Pharmacy Haven or Nursing Nightmare?Patient-controlled analgesia typically consists of opioids or local anesthetics, but it may also include non-opioid analgesics or other medications.
Latest:
Little Pills, Big Risks: The Untold Dangers of Referring to Low-Dose Aspirin as 'Baby Aspirin’Aspirin, known as acetylsalicylic acid, has been marketed in ways that have de-emphasized potential risks to children.
Latest:
Comprehensive Management of Multiple Sclerosis: The Vital Role of PharmacistsMultiple sclerosis is a debilitating disease affecting many Americans. Pharmacists can help patients control the symptoms that impact their quality of life.
Latest:
Sleep and Treatments in InsomniaPharmacists should be vigilant in recognizing medications that are causing insomnia in a patient's profile or electronic medical record.
Latest:
Developing a Health-System Controlled Substance Monitoring ProgramIt is vital to have a robust controlled substance monitoring program to promptly identify and mitigate drug diversion.
Latest:
Updates on 2022 Changes to the American Diabetes Association Standards of CareMetformin has been the drug of choice for the treatment of diabetes since the 1950s, but new changes suggest the consideration of SGLT-2 inhibitors or GLT-1 agonists.
